Costs associated with the merger: $14 million
All four companies will operate as wholly owned subsidiaries of Coram. However, Coram will consolidate operations of each company as a cost-effective measure. The company's new corporate headquarters will be located in Boulder, Colo.
The merger will be accounted for as a pooling of interests for accounting and financial reporting purposes.
Coram will have 42.3 million shares outstanding upon completion of the merger.
Coram's seven-member board of directors will include four executives designated by T2, and one each from Curaflex, HealthInfusion and Medisys.
Once the merger is completed, Coram will begin trading on the New York Stock Exchange under the symbol CRH.
Source: Coram proxy filed with the Securities and Exchange Commission